215 related articles for article (PubMed ID: 28685204)
1. Time course of the antiplatelet effect after switching to clopidogrel from initial prasugrel therapy in patients with acute coronary syndrome.
Furuse E; Takano H; Yamamoto T; Kubota Y; Yoshizane T; Kitamura M; Miyachi H; Hosokawa Y; Shimizu W
Heart Vessels; 2017 Dec; 32(12):1432-1438. PubMed ID: 28685204
[TBL] [Abstract][Full Text] [Related]
2. VERifyNow in DIabetes high-on-treatment platelet reactivity: a pharmacodynamic study on switching from clopidogrel to prasugrel.
Cubero Gómez JM; Acosta Martínez J; Mendias Benítez C; Díaz De La Llera LS; Fernández-Quero M; Guisado Rasco A; Villa Gil-Ortega M; Sánchez González Á
Acta Cardiol; 2015 Dec; 70(6):728-34. PubMed ID: 26717223
[TBL] [Abstract][Full Text] [Related]
3. Changes in P2Y12 reaction units after switching treatments from prasugrel to clopidogrel in Japanese patients with acute coronary syndrome followed by elective coronary stenting.
Ueno T; Koiwaya H; Sasaki KI; Katsuki Y; Katsuda Y; Murasato Y; Shimamatsu J; Umeji K; Otsuka Y; Kawasaki T; Shibata Y; Fukumoto Y
Cardiovasc Interv Ther; 2017 Oct; 32(4):341-350. PubMed ID: 27488859
[TBL] [Abstract][Full Text] [Related]
4. Switching patients from clopidogrel to prasugrel in acute coronary syndrome: impact of the clopidogrel loading dose on platelet reactivity.
Lhermusier T; Lipinski MJ; Drenning D; Marso S; Chen F; Torguson R; Waksman R
J Interv Cardiol; 2014 Aug; 27(4):365-72. PubMed ID: 25041356
[TBL] [Abstract][Full Text] [Related]
5. Prasugrel overcomes high on-clopidogrel platelet reactivity in the acute phase of acute coronary syndrome and maintains its antiplatelet potency at 30-day follow-up.
Koziński M; Obońska K; Stankowska K; Navarese EP; Fabiszak T; Stolarek W; Kasprzak M; Siller-Matula JM; Rość D; Kubica J; De Servi S
Cardiol J; 2014; 21(5):547-56. PubMed ID: 24671900
[TBL] [Abstract][Full Text] [Related]
6. Pharmacodynamic Effects of Switching From Prasugrel to Ticagrelor: Results of the Prospective, Randomized SWAP-3 Study.
Franchi F; Faz GT; Rollini F; Park Y; Cho JR; Thano E; Hu J; Kureti M; Aggarwal N; Durairaj A; Been L; Zenni MM; Guzman LA; Suryadevara S; Antoun P; Bass TA; Angiolillo DJ
JACC Cardiovasc Interv; 2016 Jun; 9(11):1089-98. PubMed ID: 27013060
[TBL] [Abstract][Full Text] [Related]
7. Decrease in high on-treatment platelet reactivity (HPR) prevalence on switching from clopidogrel to prasugrel: insights from the switching anti-platelet (SWAP) study.
Saucedo JF; Angiolillo DJ; DeRaad R; Frelinger AL; Gurbel PA; Costigan TM; Jakubowski JA; Ojeh CK; Duvvuru S; Effron MB;
Thromb Haemost; 2013 Feb; 109(2):347-55. PubMed ID: 23223867
[TBL] [Abstract][Full Text] [Related]
8. Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in Japanese patients with stable coronary artery disease.
Nishi T; Ariyoshi N; Nakayama T; Fujimoto Y; Sugimoto K; Takahara M; Wakabayashi S; Koshizaka M; Hanaoka H; Kobayashi Y
Circ J; 2015; 79(11):2439-44. PubMed ID: 26310876
[TBL] [Abstract][Full Text] [Related]
9. Transferring from clopidogrel loading dose to prasugrel loading dose in acute coronary syndrome patients. High on-treatment platelet reactivity analysis of the TRIPLET trial.
Diodati JG; Saucedo JF; Cardillo TE; Jakubowski JA; Henneges C; Effron MB; Lipkin FR; Walker JR; Duvvuru S; Sundseth SS; Fisher HN; Angiolillo DJ
Thromb Haemost; 2014 Aug; 112(2):311-22. PubMed ID: 24718367
[TBL] [Abstract][Full Text] [Related]
10. Impact of low-dose prasugrel on platelet reactivity and cardiac dysfunction in acute coronary syndrome patients requiring primary drug-eluting stent implantation: A randomized comparative study.
Kitano D; Takayama T; Fukamachi D; Migita S; Morikawa T; Tamaki T; Kojima K; Mineki T; Murata N; Akutsu N; Sudo M; Hiro T; Hirayama A; Okumura Y
Catheter Cardiovasc Interv; 2020 Jan; 95(1):E8-E16. PubMed ID: 30983087
[TBL] [Abstract][Full Text] [Related]
11. MULTInational non-interventional study of patients with ST-segment elevation myocardial infarction treated with PRimary Angioplasty and Concomitant use of upstream antiplatelet therapy with prasugrel or clopidogrel--the European MULTIPRAC Registry.
Clemmensen P; Grieco N; Ince H; Danchin N; Goedicke J; Ramos Y; Schmitt J; Goldstein P;
Eur Heart J Acute Cardiovasc Care; 2015 Jun; 4(3):220-9. PubMed ID: 25182465
[TBL] [Abstract][Full Text] [Related]
12. Prasugrel effectively reduces the platelet reactivity units in patients with genetically metabolic dysfunction of cytochrome P450 2C19 who are treated with long-term dual antiplatelet therapy after undergoing drug-eluting stent implantation.
Shimamatsu J; Sasaki KI; Katsuki Y; Kawasaki T; Murasato Y; Ajisaka H; Yokoi H; Tashiro H; Harada A; Hirakawa Y; Ishizaki Y; Ishimatsu T; Kagiyama K; Fukumoto Y; Kakuma T; Ueno T
Heart Vessels; 2020 Mar; 35(3):312-322. PubMed ID: 31549178
[TBL] [Abstract][Full Text] [Related]
13. Optimal cutoff value of P2Y12 reaction units to prevent major adverse cardiovascular events in the acute periprocedural period: post-hoc analysis of the randomized PRASFIT-ACS study.
Nakamura M; Isshiki T; Kimura T; Ogawa H; Yokoi H; Nanto S; Takayama M; Kitagawa K; Ikeda Y; Saito S
Int J Cardiol; 2015 Mar; 182():541-8. PubMed ID: 25679803
[TBL] [Abstract][Full Text] [Related]
14. Prasugrel in Clopidogrel Nonresponders Undergoing Percutaneous Coronary Intervention: The RECLOSE-3 Study (REsponsiveness to CLOpidogrel and StEnt Thrombosis).
Valenti R; Marcucci R; Comito V; Marrani M; Cantini G; Migliorini A; Parodi G; Gensini GF; Abbate R; Antoniucci D
JACC Cardiovasc Interv; 2015 Oct; 8(12):1563-70. PubMed ID: 26386764
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of ex vivo autologous and in vivo platelet transfusion in the reversal of P2Y12 inhibition by clopidogrel, prasugrel, and ticagrelor: the APTITUDE study.
O'Connor SA; Amour J; Mercadier A; Martin R; Kerneis M; Abtan J; Brugier D; Silvain J; Barthélémy O; Leprince P; Montalescot G; Collet JP;
Circ Cardiovasc Interv; 2015 Nov; 8(11):e002786. PubMed ID: 26553698
[TBL] [Abstract][Full Text] [Related]
16. Concomitant proton-pump inhibitor use, platelet activity, and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel and managed without revascularization: insights from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes trial.
Nicolau JC; Bhatt DL; Roe MT; Lokhnygina Y; Neely B; Corbalán R; Leiva-Pons JL; Martinez F; Goodman SG; Winters KJ; Verheugt FW; Armstrong PW; White HD; Fox KA; Prabhakaran D; Ohman EM;
Am Heart J; 2015 Oct; 170(4):683-694.e3. PubMed ID: 26386792
[TBL] [Abstract][Full Text] [Related]
17. Effects of Ticagrelor Versus Clopidogrel in Troponin-Negative Patients With Low-Risk ACS Undergoing Ad Hoc PCI.
Angiolillo DJ; Franchi F; Waksman R; Sweeny JM; Raveendran G; Teng R; Zhao Y; Carlson G; Khan N; Mehran R
J Am Coll Cardiol; 2016 Feb; 67(6):603-613. PubMed ID: 26868683
[TBL] [Abstract][Full Text] [Related]
18. Comparison of platelet aggregation response in switching regimen from prasugrel to clopidogrel between CYP2C19 extensive versus non-extensive metabolizers.
Ebisawa S; Ueki Y; Mochidome T; Senda K; Nishimura H; Saigusa T; Miura T; Motoki H; Koyama J; Ikeda U
Cardiovasc Interv Ther; 2018 Jul; 33(3):277-284. PubMed ID: 28681220
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Prasugrel Compared With Clopidogrel for Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.
Wang A; Lella LK; Brener SJ
Am J Ther; 2016; 23(6):e1637-e1643. PubMed ID: 24942006
[TBL] [Abstract][Full Text] [Related]
20. Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy.
Gurbel PA; Erlinge D; Ohman EM; Neely B; Neely M; Goodman SG; Huber K; Chan MY; Cornel JH; Brown E; Zhou C; Jakubowski JA; White HD; Fox KA; Prabhakaran D; Armstrong PW; Tantry US; Roe MT;
JAMA; 2012 Nov; 308(17):1785-94. PubMed ID: 23117779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]